REFERENCES:
1. Negi A, Ramarao P, Kumar R: Recent Advancements in Small Molecule Inhibitors of Insulinlike Growth Factor-1 Receptor (IGF-1R) Tyrosine Kinase as Anticancer agents. Mini reviews in medicinal chemistry 2013, 13 (5); 653-681.
2. Negi A, Koul S, Gupta P, Garg P, Kumar R: Cystathionine β Lyase like Protein with Pyridoxal Binding Domain Characterized in Leishmania Major by Comparative Sequence Analysis and Homology Modelling. 2013.
3. Lichtenstein LM: The immediate allergic response: in vitro separation of antigen activation, decay and histamine release. The Journal of Immunology 1971, 107 (4); 1122-1130.
4. Sicherer SH, Leung DY: Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects. Journal of allergy and clinical immunology 2007, 119 (6); 1462-1469.
5. Akdis CA, Blaser K: Histamine in the immune regulation of allergic inflammation. Journal of allergy and clinical immunology 2003, 112 (1); 15-22.
6. Ogawa Y, Grant JA: Mediators of anaphylaxis. Immunology and allergy clinics of North America 2007, 27 (2); 249-260.
7. Williams CM, Galli SJ: The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. Journal of Allergy and Clinical Immunology 2000, 105 (5); 847-859.
8. R Naik S, M Wala S: Inflammation, Allergy and Asthma, Complex Immune Origin Diseases: Mechanisms and Therapeutic Agents. Recent patents on inflammation & allergy drug discovery 2013, 7 (1); 62-95.
9. Josephs DH, Spicer JF, Corrigan CJ, Gould HJ, Karagiannis SN: Epidemiological associations of allergy, IgE and cancer. Clinical & Experimental Allergy 2013, 43 (10); 1110-1123.
10. Jackson AD: Airway goblet-cell mucus secretion. Trends in pharmacological sciences 2001, 22 (1); 39-45.
11. Solley G, Gleich G, Jordon R, Schroeter A: The late phase of the immediate wheal and flare skin reaction. Its dependence upon IgE antibodies. Journal of Clinical Investigation 1976, 58 (2); 408.
12. Pumphrey R: Lessons for management of anaphylaxis from a study of fatal reactions. Clinical and experimental allergy 2000, 30 (8); 1144-1150.
13. Trocme SD, Gleich GJ, Kephart GM, Zieske JD: Eosinophil granule major basic protein inhibition of corneal epithelial wound healing. Investigative ophthalmology & visual science 1994, 35 (7); 3051-3056.
14. Romagnani S: Cytokines and chemoattractants in allergic inflammation. Molecular immunology 2002, 38 (12); 881-885.
15. Kinet J-P: The high-affinity IgE receptor (FcεRI): from physiology to pathology. Annual review of immunology 1999, 17 (1); 931-972.
16. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392 (6673); 245-252.
17. Sicherer SH, Leung DY: Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insect stings. Journal of allergy and clinical immunology 2004, 114 (1); 118-124.
18. Robbie-Ryan M, Brown M: The role of mast cells in allergy and autoimmunity. Current opinion in immunology 2002, 14 (6); 728-733.
19. Simons F, Frew AJ, Ansotegui IJ, Bochner BS, Golden DB, Finkelman FD, Leung DY, Lotvall J, Marone G, Metcalfe DD: Risk assessment in anaphylaxis: current and future approaches. Journal of allergy and clinical immunology 2007, 120 (1); S2-S24.
20. Worm M, Babina M, Hompes S: Causes and risk factors for anaphylaxis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2013, 11 (1); 44-50.
21. Kemp SF, Lockey RF: Anaphylaxis: a review of causes and mechanisms. Journal of allergy and clinical immunology 2002, 110 (3); 341-348.
22. Simons FER, Ardusso LR, Dimov V, Ebisawa M, El-Gamal YM, Lockey RF, Sanchez-Borges M, Senna GE, Sheikh A, Thong BY: World Allergy Organization Anaphylaxis Guidelines: 2013 Update of the Evidence Base. International archives of allergy and immunology 2013, 162 (3); 193-204.
23. Brown SG, Stone SF, Fatovich DM, Burrows SA, Holdgate A, Celenza A, Coulson A, Hartnett L, Nagree Y, Cotterell C: Anaphylaxis: Clinical patterns, mediator release, and severity. Journal of allergy and clinical immunology 2013.
24. Juel J: Cardiac arrest due to anaphylactic shock: case report. Reactions 2013, 1467; 36-31.
25. Barach EM, Nowak RM, Lee TG, Tomlanovich MC: Epinephrine for treatment of anaphylactic shock. JAMA: the journal of the American Medical Association 1984, 251 (16); 2118-2122.
26. Pushparaj PN, Tay HK, H'ng SC, Pitman N, Xu D, McKenzie A, Liew FY, Melendez AJ: The cytokine interleukin-33 mediates anaphylactic shock. Proceedings of the National Academy of Sciences 2009, 106 (24); 9773-9778.
27. Cui H, Okamoto Y, Yoshioka K, Du W, Takuwa N, Zhang W, Asano M, Shibamoto T, Takuwa Y: Sphingosine-1-phosphate receptor 2 protects against anaphylactic shock through suppression of endothelial nitric oxide synthase in mice. Journal of Allergy and Clinical Immunology 2013.
.png)
